Spyre Therapeutics, Inc. (SYRE)
Market Cap | 1.41B |
Revenue (ttm) | n/a |
Net Income (ttm) | -214.90M |
Shares Out | 51.43M |
EPS (ttm) | -5.79 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,165,800 |
Open | 26.86 |
Previous Close | 26.90 |
Day's Range | 26.82 - 28.48 |
52-Week Range | 9.50 - 47.97 |
Beta | 2.91 |
Analysts | Strong Buy |
Price Target | 48.57 (+76.62%) |
Earnings Date | Nov 7, 2024 |
About SYRE
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-α4β7)... [Read more]
Financial Performance
In 2023, Spyre Therapeutics's revenue was $886,000, a decrease of -61.96% compared to the previous year's $2.33 million. Losses were -$338.79 million, 304.2% more than in 2022.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price forecast is $48.57, which is an increase of 76.62% from the latest price.
News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NAS...
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
WALTHAM, Mass. , Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, ...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
WALTHAM, Mass. , Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, ...
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing
SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting ...
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
WALTHAM, Mass. , Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, ...
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fou...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, r...
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
WALTHAM, Mass. , Oct. 30, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combin...
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating robust preclinical ...
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's...
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
WALTHAM, Mass. , Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, r...
Spyre Therapeutics to Participate in Upcoming Investor Conference
WALTHAM, Mass. , Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combi...
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an ...
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks compared to dosing every two weeks for s...
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
WALTHAM, Mass. , May 29, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering...
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
WALTHAM, Mass. , May 15, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering...
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin first-in-human studies in the second quart...
Spyre Therapeutics Announces $180 Million Private Placement
WALTHAM, Mass. , March 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutic...
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE" SPY001, an anti-α4β7 antibo...
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
WALTHAM, Mass. , Feb. 26, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineerin...
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
WALTHAM, Mass. , Feb. 8, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering...
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
WALTHAM, Mass. , Feb. 5, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering...
Spyre Therapeutics to Present at Upcoming Investor Conference
WALTHAM, Mass. , Nov. 28, 2023 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform ...
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of...
Aeglea BioTherapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to trans...